OncoMatch/Clinical Trials/NCT04991870
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Is NCT04991870 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Cord Blood-derived Expanded Allogeneic Natural Killer Cells for recurrent gliosarcoma.
Treatment: Cord Blood-derived Expanded Allogeneic Natural Killer Cells — This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Allowed: IDH1 wild-type
recurrent IDH WT glioblastoma
Allowed: IDH1 mutation
recurrent IDHmutant grade 4 astrocytoma
Disease stage
Required: Stage GRADE 4 (World Health Organization)
Grade: 4 (World Health Organization)
World Health Organization grade 4 recurrent astrocytoma
Demographics
Prior therapy
Must have received: radiation therapy
have received prior radiation and temozolomide therapy
Must have received: alkylating agent (temozolomide)
have received prior radiation and temozolomide therapy
Cannot have received: Gliadel (Gliadel)
Has received prior therapy with Gliadel
Cannot have received: VEGF inhibitor (bevacizumab)
Has received prior therapy with...bevacizumab
Cannot have received: interstitial brachytherapy
Has received prior interstitial brachytherapy
Cannot have received: implanted chemotherapy
Has received prior...implanted chemotherapy
Cannot have received: local injection or convection enhanced delivery
Has received prior...therapeutics delivered by local injection or convection enhanced delivery
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody within the last three months
Lab requirements
Blood counts
WBC ≥ 3 x 10^9/L, ANC ≥ 1.5 x 10^9/L, lymphocyte count ≥ 0.5 x 10^9/L, platelet count ≥ 100 x 10^9/L, Hgb ≥ 9 g/dL (in absence of blood transfusion)
Kidney function
creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for participant with creatinine levels > 1.5 x institutional ULN
Liver function
total bilirubin level ≤ 1.5 x ULN, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, INR ≤ 1.5
Adequate hematological function... Adequate hepatic function... Adequate renal function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04991870 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Gliadel, VEGF inhibitor, interstitial brachytherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage GRADE 4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages